دورية أكاديمية
Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib
| العنوان: | Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib |
|---|---|
| المؤلفون: | Fischer, Kristina, Aringer, Martin, Steininger, Julian, Heil, Julius, Beissert, Stefan, Abraham, Susanne, Günther, Claudia |
| حالة النشر: | publishedVersion |
| بيانات النشر: | Oxford University Press, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Original Material: | urn:nbn:de:bsz:14-qucosa2-920973 |
| مصطلحات موضوعية: | Autoimmune disease, treatment, dermatology, Autoimmunerkrankung, Behandlung, Dermatologie, info:eu-repo/classification/ddc/610, ddc:610 |
| الوصف: | Dear Editor, Dermatomyositis (DM) is a rare autoimmune disease with cutaneous and systemic involvement significantly impairing quality of life. Current treatment options are unspecific and often induce only partial remission, especially in DM‐associated panniculitis. The pathogenesis of the disease is fairly unknown; however, induction of type I interferon (IFN) and its IFN‐stimulated genes (ISGs) was discovered in patients’ blood, muscle and skin.1 Inhibiting the activation of Janus kinase (JAK)‐transmitting signals of the type I IFN receptor is a valuable therapeutic option, and the efficacy of the JAK1 and JAK2 inhibitor baricitinib was reported in eight patients with juvenile DM and in two patients with adult DM.2–6 The prominent type I IFN signature in DM prompted us to treat three patients with classic adult DM with the JAK inhibitor baricitinib.1 Patient 1 had experienced a recurrent disease course for 25 years. She had previously received immunosuppressive therapy and intravenous immunoglobulin (IVIG). Partial remission was achieved with low‐dose prednisolone (5 mg per day), methotrexate, hydroxychloroquine and adalimumab. Nevertheless, she presented with a new disease flare with violaceous erythema prone to the face, décolleté, neck and periungual area, but normal muscle enzymes (Figure 1a). The therapy with methotrexate and adalimumab was terminated due to an increase in liver enzymes. Thereafter, tofacitinib was started but was not well tolerated because of lactose intolerance in the patient. Therefore, the therapy was changed to baricitinib 4 mg daily. The neck, facial and periungual erythema completely regressed within 5 months of treatment (Figure 1a). |
| Original Identifier: | oai:qucosa:de:qucosa:92097 |
| نوع الوثيقة: | article Text |
| اللغة: | English |
| تدمد: | 1365-2133 |
| DOI: | 10.1111/bjd.21252 |
| الإتاحة: | https://tud.qucosa.de/id/qucosa%3A92097Test https://tud.qucosa.de/api/qucosa%3A92097/attachment/ATT-0Test/ |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsndl.DRESDEN.oai.qucosa.de.qucosa.92097 |
| قاعدة البيانات: | Networked Digital Library of Theses & Dissertations |
| تدمد: | 13652133 |
|---|---|
| DOI: | 10.1111/bjd.21252 |